Hirai T, Waddell T K, Puskas J D, Wada H, Hitomi S, Gorczynski R M, Slutsky A S, Patterson G A
Department of Surgery, University of Toronto, Toronto General Hospital, Ontario, Canada.
J Thorac Cardiovasc Surg. 1993 Jan;105(1):1-8.
We examined the hypothesis that FK 506 would induce graft acceptance after lung transplantation. Left lung allotransplantation was performed in size-matched mongrel dogs allocated to control (no immunosuppression, n = 3) and FK 506 (n = 5) groups. FK 506 (1.2 mg/kg intramuscularly every day) was given on posttransplantation days 0, 1, and 2. No other immunosuppressive agents were administered to either group. Chest x-ray and transplant lung physiologic assessments were performed on the fifth day and weekly thereafter. On day 29 an open lung biopsy and a third-party skin graft were performed. Lymphocytes were harvested and frozen from the recipient peripheral blood before transplantation and on days 8 and 29 afterwards for assessment in mixed lymphocyte reaction. Dogs were killed when their chest x-ray films showed allograft opacification or when the skin graft was rejected. Control lungs were all rejected after a median of 5 days. In the FK 506 group, one of five dogs aspirated during the fifteenth-day assessment and was killed, on the twenty-ninth day, because of severe rejection. At day 29, in the other four dogs, the transplanted lung yielded an arterial oxygen tension of 613 +/- 25 mm Hg (mean +/- standard deviation) and lung biopsy specimens showed no abnormalities histologically. These four dogs rejected third-party skin grafts after a median of 10 days. In two FK 506 dogs, mixed lymphocyte reaction at day 8 showed suppression of proliferation responses against donor and third-party lymphocytes. By day 29 responses against third-party lymphocytes had returned to almost preoperative levels, whereas antidonor responses were still suppressed. After skin graft rejection and killing, one of four dogs showed no sign of rejection, and the other three showed minimal to mild lung rejection at the time they were killed. We conclude that a 3-day course of 1.2 mg/kg of FK 506 induced prolonged graft acceptance after lung transplantation in dogs.
我们检验了FK 506能诱导肺移植后移植物被接受这一假说。对大小匹配的杂种犬进行左肺同种异体移植,将其分为对照组(不进行免疫抑制,n = 3)和FK 506组(n = 5)。在移植后的第0、1和2天给予FK 506(每天1.2 mg/kg肌肉注射)。两组均未给予其他免疫抑制剂。在第5天及之后每周进行胸部X线和移植肺生理评估。在第29天进行开放性肺活检和第三方皮肤移植。在移植前以及之后的第8天和第29天,从受体外周血中采集淋巴细胞并冷冻,用于混合淋巴细胞反应评估。当胸部X线片显示同种异体移植物浑浊或皮肤移植被排斥时,将犬处死。对照组的肺在中位时间5天后全部被排斥。在FK 506组中,五只犬中有一只在第15天评估时误吸,并在第29天因严重排斥反应而被处死。在第29天,其他四只犬的移植肺动脉血氧分压为613±25 mmHg(均值±标准差),肺活检标本在组织学上未显示异常。这四只犬在中位时间10天后排斥第三方皮肤移植。在两只接受FK 506治疗的犬中,第8天的混合淋巴细胞反应显示对供体和第三方淋巴细胞的增殖反应受到抑制。到第29天,对第三方淋巴细胞的反应已恢复到几乎术前水平,而对供体的反应仍受到抑制。在皮肤移植被排斥并将犬处死时,四只犬中有一只没有排斥迹象,另外三只在处死时显示出轻微至中度的肺排斥反应。我们得出结论,1.2 mg/kg的FK 506进行为期3天的疗程可诱导犬肺移植后移植物被长期接受。